Floatz Rating
CCC50/100
Confidence
Indicative
Sponsor
CRISPR Therapeutics AG
Modality
UNKNOWN
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
37Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05795595CT.gov A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Cervical Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| ctx131 (this asset) | CRISPR Therapeutics AG | P1/2 | CCC · 50 |
| Carboplatin | Advenchen Laboratories, LLC | P3 | BB |
| Hepatitis B Virus Vaccine | Eunice Dube | P4 | BB |
| Gardasil 9 Vaccine | Eunice Dube | P4 | BB |
| Nogitecan | Advenchen Laboratories, LLC | P3 | BB |
| Pembrolizumab | Mayo Clinic | P2 | BB |
| Adriamycin | Advenchen Laboratories, LLC | P3 | B |
| Trastuzumab | National Cancer Institute (NCI) | P2 | B |
| Durvalumab | M.D. Anderson Cancer Center | P2 | B |
+42 more in the Cervical Carcinoma cohort
Other indications for ctx131
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Malignant Pleural Mesothelioma | — | P1/2 | CCC · 52 |
| T-Cell Non-Hodgkin Lymphoma | — | P1/2 | CCC · 50 |
| Carcinoma Of Esophagus | — | P1/2 | CCC · 48 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. ctx131 in Cervical Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ctx131-cervical-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →